(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest

Benzinga14:30 ET

Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One

BenzingaNov 27 08:12 ET

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BenzingaNov 26 22:37 ET

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)

TipRanksNov 25 01:00 ET · Ratings

BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsNov 21 05:31 ET · Ratings

Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties

TipRanksNov 21 05:28 ET · Ratings